DaVita Inc.

• Valuation9.5 / 10
• Management6.5 / 10
• Balance Sheet3.5 / 10
• Profitability7 / 10
• Revenue Growth6 / 10
• Risk Assessment4 / 10
• Competitive Moat7 / 10
• Earnings Quality9 / 10
• Capital Efficiency6.5 / 10

The primary risk that would challenge this view is a compression in commercial reimbursement rates or clinical wage inflation that causes clinic operating margins to fall below 12.0%. Because commercial contracts cross-subsidize government programs, such margin erosion would compress annual free cash flow below $800,000,000, elevate debt service pressure on $12,874,331,000 in total debt, and force a suspension of share repurchases.^2,4,5

The primary driver of the thesis is DaVita's entrenched nationwide clinic network delivering non-discretionary dialysis, generating $13,643,069,000 in revenue and $1,310,636,000 in free cash flow. Management directs this excess cash flow into aggressive share repurchases, shrinking diluted shares from 93,182,000 in FY2023 to 75,885,000 in FY2025, systematically compounding per-share earnings toward our Fair value of $386.49.^4,5

الحالي:$1,310,636,000

Limitation: Terminal value is 70.1% of this model's value, above the 60% level at which the methodology flags concentration; the value leans on the years beyond the explicit forecast.

The bull path assumes accelerated expansion in integrated kidney care programs, favorable commercial payer renewals, and enhanced clinical staffing productivity. Accelerated share repurchases compound diluted earnings per share, driving the target to $490.58 with an estimated probability of 20.0% and a return of 166.8% over $183.86.

Surplus cash after capital spending funds share repurchases and debt reduction; lower cash flow directly restricts buybacks and slows per-share growth.

Total debt stands at $12,874,331,000 in FY2025 ($13,406,474,240 at Q2 2026), representing 53.18% of capital structure.

Higher borrowing costs on refinancing will absorb free cash flow and constrain buyback velocity.